ReviewCurrent opinion in HIV and AIDS2025
Understanding the HIV-specific T-cell response to immune checkpoint blockade: what can we learn from cancer immunotherapy?
Review in Current opinion in HIV and AIDS, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Immune checkpoint inhibitors in HIV infection: current evidence on viral reservoir regulation and immune restoration.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewThis review examines the potential of immune checkpoint blockade (ICB) to enhance HIV-specific T-cell responses, leveraging insights from cancer immunotherapy to tackle persistent challenges in achieving long-term potent immune response to keep the virus in check. By highlighting lessons from oncology, we aim to discuss innovative strategies to improve HIV treatment outcomes and advance the search for a functional cure. RECENT
findingsICB extends beyond targeting PD-1 and CTLA-4, with novel therapies and engineered approaches in cancer also holding promise for HIV treatment. HIV-specific T-cell exhaustion, stemness, T-cell receptor clonal replacement, and antigen load critically influence ICB success, emphasizing the complexity and need for research on innovative strategies that can further enhance treatment efficacy in the context of HIV. SUMMARY: While ICB shows promising potential, its role in HIV cure strategies requires further exploration in clinical trials with people with HIV (PWH). Future research should focus on advancing ICB as a tool for durable HIV control by investigating novel immune checkpoint targets, bispecific antibodies, minimizing toxicity, and identifying biomarkers for effective ICB responses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.